bioRxiv Science⌕ Search

Biology subjects

Jie, G.

Publications and source records attributed to Jie, G..

2 recordsLinked to original sources

The splicing isoform Foxpdelta2 releases the autoinhibitory conformation and differentially regulates tTregs and pTregs homeostasis

Foxp3 is the master transcription factor for the development and function of regulatory T cells (Tregs). So far, little is known about whether the conformation change in Foxp3 could impact the Tregs biology. Alternative splicing of human Foxp3 results in the expression of two major isoforms: the full-length protein or an exon 2-deleted protein (Foxp3{Delta}2). Here, AlphaFold2 structure predictions and in vitro experiments demonstrated that the N-terminal domain of Foxp3 inhibits DNA binding by moving toward the C-terminus and that this movement is mediated by exon 2. Consequently, we generated exon 2 deficient mice and found Foxp3{Delta}2-bearing Tregs in the peripheral lymphoid organ were less sensitive to TCR due to the enhanced binding of Foxp3{Delta}2 to the Batf promoter and were unsusceptible to IL-2. In contrast, among ROR{gamma}t+ Tregs in the large intestine, Foxp3{Delta}2 Tregs expressed much more ROR{gamma}t-related genes, and more strikingly, the deletion of exon 2 of Foxp3 conferred a competitive advantage over WT ROR{gamma}t+ Tregs. Together, our results reveal that alternative splicing of exon 2 generates a constitutively active form of Foxp3, which plays a differential role in regulating tTregs and pTregs homeostasis. HighlightsO_LIFoxp3{Delta}2 broke the inhibitory loop and generated constitutive DNA-binding activity. C_LIO_LIFoxp3 isoforms differentially regulate tTregs and pTregs homeostasis C_LIO_LIFoxp3{Delta}2-bearing Tregs in the peripheral lymphoid organ were less sensitive to TCR and were unsusceptible to IL-2 C_LIO_LIFoxp3{Delta}2 ROR{gamma}t+ pTregs benefited them for better adapting to the gut environmental conditions C_LI

immunology↗

Novel Small Molecular Compound AE-848 Showed Potent Inhibitory Activity Against Human Hepatoblastoma Cells

PurposeAE-848/33345007, is a novel small molecular compound that was independently synthesized by our laboratory. The aim of the current study was to investigate potential therapeutic effects of the small molecule compound AE-848 on human hepatoblastoma cells. MethodsHuman hepatoblastoma cell line HepG2 was cultured under different concentrations of AE-848. MTT assay was used to detect the inhibitory ability of AE-848 on the activity of this cell line, while flow cytometry was applied to quantify apoptosis. Western-blot technique was used to determine expression levels of signaling pathway-associated molecules. The antitumor in vivo activity of AE-848 against hepatoblastoma was evaluated using hepatoblastoma-bearing nude mice randomly divided into AE-848 (experimental) and saline (control) groups respectively. Changes in survival and tumor sizes were compared between these two groups. ResultsAE-848 significantly inhibited proliferation and induced apoptosis of HepG2 cells, and induced activation of PI3K/Akt/mTOR signaling pathways. More importantly, AE-848 administration significantly inhibited tumor growth and prolonged survival of hepatoblastoma-bearing mice. ConclusionAE-848 had a strong anti-hepatoblastoma activity both in vitro and in vivo, indicating the importance of developing AE-848 as a potential drug for hepatoblastoma treatment.

cancer biology↗